BPC-157: The Complete Research Profile — Mechanism, Dosing, Benefits & Side Effects
Last updated: April 14, 2026 · 18 min read · Reviewed by Grey Peptides Editorial Board
TL;DR
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. It is the most extensively studied repair peptide in preclinical research, with over 100 animal studies demonstrating accelerated healing of tendons, ligaments, muscles, bones, nerves, the GI tract, and the cardiovascular system. Its primary mechanisms are angiogenesis (new blood vessel formation via VEGF upregulation), nitric oxide system modulation, and growth hormone receptor expression enhancement. Human clinical data is extremely limited — one small pilot study in ulcerative colitis — but the breadth and consistency of animal evidence is unusual for a peptide compound. The standard research dosing is 250–500 mcg injected subcutaneously 1–2 times daily near the target area, typically for 4–8 weeks.
→ Explore BPC-157's full profile interactively in our Peptide Encyclopedia.
→ Calculate your exact BPC-157 dosing with the Reconstitution Calculator.
Table of Contents
- What Is BPC-157?
- Origin & Discovery
- Molecular Profile
- Mechanism of Action
- Preclinical Research Overview
- Human Clinical Evidence
- Dosing Protocols
- Reconstitution & Administration
- Side Effects & Safety Profile
- Legal & Regulatory Status
- BPC-157 vs Other Repair Peptides
- Stacking BPC-157
- Frequently Asked Questions
- Sources
What Is BPC-157?
BPC-157 is a synthetic peptide consisting of 15 amino acids (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from Body Protection Compound, a protein naturally present in human gastric juice. The "157" refers to its position within the parent protein's larger amino acid chain.
The peptide belongs to a category informally called "repair peptides" — compounds that appear to accelerate tissue healing across multiple organ systems. What distinguishes BPC-157 from other peptides in this category is the sheer volume of preclinical data. It has been studied in over 100 published animal experiments covering an unusually diverse range of tissue types, injury models, and pathological conditions.
BPC-157 is not FDA-approved for any indication. It is classified as a research compound and, as of 2024, was included on the FDA's list of substances nominated for evaluation under the 503A/503B compounding framework. Despite its regulatory ambiguity, it remains one of the most widely used peptides in the self-directed optimization and clinical peptide therapy communities.
→ New to peptides? Start with our Beginner's Guide before diving into compound-specific research.
Origin & Discovery
BPC-157 research originates from the laboratory of Predrag Sikirić at the University of Zagreb, Croatia. Sikirić's group has been the primary — and, notably, nearly the sole — research team publishing BPC-157 data since the early 1990s. This concentration of research output from a single lab is both the compound's greatest strength (deep, consistent methodology) and its most significant limitation (limited independent replication).
The discovery pathway began with the observation that gastric juice contains cytoprotective factors — proteins that protect the stomach lining from its own acid, digestive enzymes, and NSAID damage. Sikirić's team isolated a specific protective compound from human gastric juice, identified its active fragment as a 15-amino-acid sequence, and synthesized it for experimental use.
The name "Body Protection Compound" reflects the peptide's original context: a naturally occurring compound that protects the body's own tissues. Over three decades, the Zagreb group has published studies demonstrating this protective and regenerative effect in virtually every tissue type tested — gut, tendon, ligament, muscle, bone, nerve, blood vessel, brain, liver, and more.
The concentration of nearly all BPC-157 research within a single laboratory is frequently cited by skeptics as a reason for caution. Independent replication by unaffiliated research groups — the gold standard for scientific confidence — remains limited, though a small number of studies from Chinese and Korean university labs have corroborated some of the Zagreb findings.
Molecular Profile
| Property | Value |
|---|---|
| Full name | Body Protection Compound-157 |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Chain length | 15 amino acids |
| Molecular weight | 1,419.53 Da |
| Molecular formula | C₆₂H₉₈N₁₆O₂₂ |
| Stability | Stable in human gastric juice (pH 1–2) — unusual for peptides |
| Half-life | Estimated ~4 hours (not formally characterized in humans) |
| Natural source | Human gastric juice |
| CAS number | 137525-51-0 |
| Common vial sizes | 5 mg, 10 mg |
| Storage (lyophilized) | Room temperature stable, refrigeration extends shelf life |
| Storage (reconstituted) | 2–8°C, use within 28 days |
One of BPC-157's most notable physical properties is its gastric acid stability. Most peptides degrade rapidly in the acidic, protease-rich environment of the stomach — which is why most peptides require injection. BPC-157's stability in gastric juice has led to research into oral and sublingual administration routes, though injectable subcutaneous delivery remains the primary method used in both research protocols and clinical practice.
→ Look up any term in this table at the Peptide Glossary.
Mechanism of Action
BPC-157 does not appear to work through a single receptor or signaling pathway. Instead, it modulates several interconnected systems simultaneously. This multi-pathway mechanism is what likely explains its observed effects across so many different tissue types.
1. VEGF Upregulation & Angiogenesis
BPC-157's most well-characterized mechanism is its ability to upregulate vascular endothelial growth factor (VEGF), the master signaling molecule for angiogenesis — the formation of new blood vessels from existing vasculature.
New blood vessels deliver oxygen, nutrients, and growth factors to damaged tissue. They also provide the route through which immune cells and repair cells reach the injury. By enhancing blood supply to damaged areas, BPC-157 addresses the fundamental bottleneck in tissue healing.
Multiple animal studies have confirmed VEGF upregulation following BPC-157 administration, including studies using VEGF-blocking agents that partially inhibited BPC-157's healing effects — suggesting that VEGF is indeed a primary mediator, though not the sole pathway. [1]
2. Nitric Oxide (NO) System Modulation
BPC-157 interacts with the nitric oxide system in a context-dependent manner. When NO levels are pathologically low (as in certain vascular injuries), BPC-157 appears to increase NO production. When NO levels are pathologically high (as in septic shock models), it appears to normalize them downward. This bidirectional modulation is unusual and suggests a regulatory rather than simply stimulatory role. [2]
Nitric oxide is critical for vasodilation, immune function, and tissue repair signaling. The ability to modulate it in context may explain BPC-157's protective effects in multiple pathological models — from hypertension to gut inflammation to CNS injury.
3. Growth Hormone Receptor (GHR) Expression
BPC-157 has been shown to upregulate growth hormone receptor expression in tendon fibroblasts and other connective tissue cells. [3] This doesn't increase circulating growth hormone levels — it makes target tissues more responsive to the GH that's already present. This mechanism is particularly relevant for tendon and ligament healing, where GH signaling plays a key role in collagen synthesis and tissue remodeling.
4. FAK-Paxillin Pathway Activation
Focal adhesion kinase (FAK) and paxillin are intracellular signaling proteins critical for cell migration, adhesion, and tissue remodeling. BPC-157 has been shown to activate this pathway, promoting the organization of repair cells at injury sites. This mechanism is complementary to TB-500's actin-based cell migration pathway, which is one reason the two peptides stack effectively. [4]
5. GABAergic & Dopaminergic Interactions
In CNS studies, BPC-157 has demonstrated interactions with the GABAergic and dopaminergic neurotransmitter systems. Animal models show protective effects against dopamine-related neurotoxicity and the ability to modulate GABA receptor sensitivity. These interactions may underlie observed anxiolytic and neuroprotective effects in animal behavior studies, though the precise receptor-level mechanisms remain under investigation. [5]
→ See how BPC-157's mechanisms compare to other repair peptides in our Comparison Tool.
Preclinical Research Overview
The scope of BPC-157's preclinical data is remarkable in its breadth. Below is a summary organized by tissue system. All studies cited are animal models unless otherwise noted.
Musculoskeletal System
Tendons. Multiple studies demonstrate accelerated healing of transected Achilles tendons in rats, with BPC-157-treated animals showing superior tendon-to-bone healing, increased collagen organization, and earlier restoration of mechanical strength compared to controls. [6]
Ligaments. Medial collateral ligament (MCL) injury models show enhanced healing with BPC-157 administration, including improved tissue organization and earlier return of biomechanical integrity. [7]
Muscles. Crushed muscle injury models demonstrate faster recovery of muscle function and reduced fibrotic scar tissue with BPC-157 treatment. The peptide also appears to counteract corticosteroid-induced muscle damage. [8]
Bone. Segmental bone defect models show enhanced bone healing with BPC-157, including increased bone mineral density at the defect site and accelerated bridging of the fracture gap. [9]
Gastrointestinal System
This is BPC-157's original research context and its deepest evidence base. Studies demonstrate protective and healing effects across:
- NSAID-induced gastric ulcers and intestinal lesions
- Inflammatory bowel disease models (both induced colitis and spontaneous models)
- Esophageal reflux damage
- Anastomotic healing (surgical reconnection of bowel segments)
- Short bowel syndrome models
- Fistula healing
- Liver damage (from alcohol, acetaminophen, and bile duct ligation) [10]
The consistency of GI protection across dozens of studies and multiple injury models is one of the strongest areas of BPC-157 evidence.
Nervous System
Peripheral nerves. Sciatic nerve crush and transection models show accelerated nerve regeneration and functional recovery with BPC-157 treatment. [11]
Central nervous system. Traumatic brain injury models demonstrate reduced brain edema, neuronal loss, and behavioral deficits. BPC-157 also shows neuroprotective effects against various neurotoxic insults, including cuprizone-induced demyelination, dopaminergic neurotoxins (MPTP), and serotonergic neurotoxins. [12]
Cardiovascular System
Studies demonstrate protection against various cardiovascular injuries including arrhythmias, congestive heart failure models, pulmonary hypertension, and thrombosis. BPC-157 has also shown the ability to accelerate blood vessel repair following surgical injury. [13]
Important Caveats
Single-lab concentration. The vast majority of this data comes from the Sikirić laboratory. While the methodology appears consistent and the results have been published in peer-reviewed journals, the limited independent replication means this evidence base carries inherent uncertainty.
Animal-to-human translation. The leap from rat models to human physiology is substantial. Many compounds that show striking results in rodents fail to translate when tested in humans. BPC-157 has not yet been adequately tested in controlled human trials.
Publication bias. It is unknown whether negative or null results exist in unpublished data. The uniformly positive publication record, while impressive, cannot rule out this possibility.
Human Clinical Evidence
As of April 2026, human clinical evidence for BPC-157 is extremely limited:
Ulcerative colitis pilot study. A small, open-label pilot study assessed BPC-157 administered as an enema in patients with ulcerative colitis. The results were described as promising, with improvements in endoscopic and clinical scores, but the study lacked a placebo control group and had a small sample size. [14]
Clinical trials registered. A Phase II clinical trial for BPC-157 in inflammatory bowel disease has been registered (Diagen, the pharmaceutical company with rights to BPC-157 development), but results have not yet been published as of this writing.
Anecdotal and clinical practice reports. A substantial body of anecdotal evidence exists from peptide therapy clinics, biohacking communities, and sports medicine practitioners. These reports frequently describe accelerated healing of soft tissue injuries, reduced joint pain, improved gut function, and decreased recovery time. While these reports align with the animal data, they do not constitute controlled clinical evidence and are subject to placebo effects, recall bias, and confounding factors.
The gap between BPC-157's extensive preclinical data and its minimal human clinical data is the central tension in evaluating this compound. The animal evidence is genuinely impressive in scope and consistency. The human evidence is nearly nonexistent by clinical research standards.
→ Read the full discussion of peptide evidence standards in our FAQ Knowledge Base.
Dosing Protocols
BPC-157 dosing in the research community has converged around a fairly narrow range, derived from body-weight scaling of effective animal doses.
Standard Dosing
| Protocol | Dose | Frequency | Duration | Target |
|---|---|---|---|---|
| Conservative start | 250 mcg | 1x daily | 2 weeks, then reassess | General healing support |
| Standard | 250 mcg | 2x daily | 4–8 weeks | Soft tissue injuries, tendinopathy |
| Aggressive | 500 mcg | 2x daily | 4–8 weeks | Significant injuries, post-surgical recovery |
| GI-focused (oral) | 250–500 mcg | 1–2x daily | 4–8 weeks | Gut healing, IBS, ulcer recovery |
Dosing Principles
Body weight scaling. The standard doses above are derived from animal studies using approximately 10 mcg/kg body weight. For a 75 kg human, this yields 750 mcg/day — which falls in the range of 250 mcg twice daily or 500 mcg once daily.
Local vs systemic injection. For musculoskeletal injuries, BPC-157 is typically injected subcutaneously as close to the injury site as anatomically practical. The rationale is that local injection maximizes peptide concentration at the target tissue. For systemic conditions (gut healing, general recovery), abdominal subcutaneous injection is standard.
Cycling. Most protocols recommend 4–8 week cycles followed by a break of equal duration. There is no established evidence for or against continuous use, but cycling is considered prudent given the limited long-term safety data.
Oral administration. BPC-157's gastric acid stability makes oral dosing theoretically viable. Some practitioners use oral BPC-157 specifically for GI conditions, reasoning that direct gut exposure maximizes local effects. Oral bioavailability for systemic effects is likely lower than injectable, though precise pharmacokinetic data in humans is unavailable.
→ Calculate exactly how many units to draw for your dose with the Reconstitution Calculator.
→ Build a complete BPC-157 protocol with timing and cycle length at the Protocol Builder.
Reconstitution & Administration
BPC-157 follows the standard peptide reconstitution process. If you are new to peptide preparation, read the complete How to Reconstitute Peptides guide first.
Quick Reference
| Parameter | Value |
|---|---|
| Common vial size | 5 mg |
| Recommended BAC water | 2 mL |
| Resulting concentration | 2.5 mg/mL (2,500 mcg/mL) |
| 250 mcg dose = | 10 units on U-100 insulin syringe |
| 500 mcg dose = | 20 units on U-100 insulin syringe |
| Doses per vial (at 250 mcg 2x/day) | 10 days |
| Doses per vial (at 500 mcg 2x/day) | 5 days |
| Storage after reconstitution | 2–8°C (refrigerator), up to 28 days |
Injection Site Selection
For musculoskeletal injuries, inject subcutaneously within a few inches of the injury site. You are not injecting into the tendon or joint — the injection goes into the fat layer under the skin near the area. BPC-157 migrates to damaged tissue from nearby subcutaneous injection sites.
For GI or systemic use, inject into abdominal subcutaneous tissue (pinch a fold of belly fat, insert needle at 45° or 90° depending on fat thickness).
→ See the interactive injection site body map at our Mixing & Administration Guide.
Side Effects & Safety Profile
BPC-157 has a favorable safety profile in the available data, though this assessment carries important caveats.
Observed in Animal Studies
BPC-157 has shown no observed toxic effects across numerous animal studies, even at doses far exceeding the standard research range. No LD50 (lethal dose) has been established because researchers have been unable to induce lethal toxicity even at very high doses. [15]
Reported in Anecdotal Human Use
The most commonly reported side effects from community use include:
Injection site reactions. Mild redness, swelling, or itching at the injection site. Typically resolves within 1–2 hours. More common with higher volumes or faster injection speed.
Nausea. Occasional, typically mild, more common with oral administration. May be dose-dependent.
Dizziness or lightheadedness. Reported infrequently. May be related to NO system modulation and transient vasodilation.
Fatigue. Some users report transient fatigue in the first few days of use. Typically resolves as the body adjusts.
Vivid dreams or sleep changes. Reported by a minority of users. Not well characterized or explained by known mechanisms.
Theoretical Concerns
Angiogenesis and cancer. BPC-157's pro-angiogenic effects raise a theoretical concern: could enhanced blood vessel formation support the growth of existing tumors, which require their own blood supply (tumor angiogenesis)? This concern has not been validated or disproven in studies. Current animal data does not show increased tumor incidence, but this has not been specifically studied in cancer-bearing animal models. Individuals with active malignancies should avoid BPC-157 until this question is resolved.
Long-term effects unknown. No long-term safety data exists in humans. The 4–8 week cycling convention is a precautionary approach, not an evidence-based limit.
→ Check BPC-157 interactions with other peptides in the Interaction Checker.
Legal & Regulatory Status
BPC-157 occupies a regulatory gray area in most jurisdictions as of 2026.
United States. BPC-157 is not FDA-approved for any medical indication. It was included on the FDA's 2024 nomination list for evaluation under the 503A/503B compounding framework. As of early 2026, the FDA's PCAC (Pharmacy Compounding Advisory Committee) has not yet issued a final determination. It can be legally purchased as a "research chemical" but not marketed for human consumption. Compounding pharmacies have continued to produce it under the existing regulatory ambiguity.
European Union. Not approved as a pharmaceutical. Available through research chemical suppliers. Individual country regulations vary.
Australia. Classified as a Schedule 4 (prescription-only) substance under the TGA. Available through compounding pharmacies with a prescription.
Canada. Not approved by Health Canada. Available through research chemical channels.
For a full country-by-country analysis, see our article: Are Peptides Legal? 2026 Guide.
BPC-157 vs Other Repair Peptides
| Feature | BPC-157 | TB-500 | GHK-Cu |
|---|---|---|---|
| Primary mechanism | Angiogenesis (VEGF) | Cell migration (actin) | ECM remodeling (collagen/elastin) |
| Best for | Tendon, ligament, GI | Systemic repair, inflammation | Skin, anti-aging, hair |
| Injection location | Near injury (local) | Anywhere (systemic) | Near target or topical |
| Half-life | ~4 hours | ~24 hours | ~12 hours |
| Dosing frequency | 1–2x daily | 2x/week (loading), 1x/week (maintenance) | 1x daily |
| Human data | 1 pilot study | None | Topical studies only |
| Gastric stability | Yes (oral viable) | No | No |
| Animal study volume | 100+ studies | ~30 studies | ~50 studies |
The key distinction: BPC-157 builds the blood supply to heal tissue, TB-500 moves repair cells to the injury, and GHK-Cu remodels the extracellular matrix. They work through genuinely different pathways, which is why the BPC-157 + TB-500 combination is the most popular repair stack.
→ Run a side-by-side comparison of any two peptides in the Comparison Tool.
→ Read the full analysis: BPC-157 vs TB-500.
Stacking BPC-157
BPC-157 is commonly combined with other peptides to broaden the repair response. The most established combinations:
BPC-157 + TB-500 (The Repair Stack)
The most widely used peptide combination for tissue healing. BPC-157 provides local angiogenesis while TB-500 provides systemic cell migration and anti-inflammatory effects. Rated "Strong Synergy" — the two peptides work through complementary, non-overlapping pathways.
→ Full protocol breakdown: BPC-157 + TB-500 Stack Guide.
BPC-157 + TB-500 + GHK-Cu (The Wolverine Stack)
Adds GHK-Cu's extracellular matrix remodeling to the repair stack. The combination addresses blood supply (BPC-157), cell migration (TB-500), and tissue structure (GHK-Cu) simultaneously. Most commonly used for comprehensive injury recovery or post-surgical healing.
BPC-157 + CJC-1295/Ipamorelin
Combines tissue repair with growth hormone optimization. BPC-157's upregulation of growth hormone receptors may enhance the effects of GH secretagogues. Used for recovery protocols that also target body composition and sleep quality.
→ Check any combination for interactions and timing conflicts at the Interaction Checker.
Frequently Asked Questions
How quickly does BPC-157 work? Most users and practitioners report noticeable improvement beginning in the first 1–2 weeks, with significant progress by weeks 3–4. The timeline varies by injury type and severity. Chronic tendinopathies may take the full 8-week cycle to show substantial improvement.
Can I take BPC-157 orally? BPC-157 is unusually stable in gastric acid, making oral administration viable. Some practitioners prefer oral dosing specifically for GI conditions (IBS, ulcerative colitis, gastric ulcers) on the theory that direct gut exposure maximizes local effects. For musculoskeletal injuries, subcutaneous injection near the injury is generally preferred.
Do I need to inject near the injury? For musculoskeletal injuries, local injection is recommended to maximize peptide concentration at the target tissue. However, some animal studies show systemic effects even with distant injection, suggesting BPC-157 does circulate and can reach tissues throughout the body. For non-localized conditions, abdominal subcutaneous injection is standard.
Is BPC-157 safe to take long-term? No long-term human safety data exists. The 4–8 week cycling convention followed by an equal rest period is a precautionary approach widely used in the peptide community. Some practitioners use it continuously for chronic conditions, but this approach is not supported by safety data.
Will BPC-157 show up on a drug test? Standard workplace drug panels do not test for peptides. WADA (World Anti-Doping Agency) has listed BPC-157 as prohibited under class S0 (non-approved substances). Athletes subject to WADA testing should not use BPC-157. See our FAQ on peptides and drug testing for details.
Can BPC-157 cause cancer? This is a common concern based on BPC-157's pro-angiogenic mechanism. No animal studies have shown increased cancer incidence, but the question has not been studied in tumor-bearing models specifically. As a precaution, individuals with active malignancies are advised to avoid BPC-157 until more data is available.
What's the difference between BPC-157 and BPC-157 acetate vs arginine salt? BPC-157 is commonly available in two salt forms: acetate and arginine (arginate). The acetate form is more widely available and used in most research studies. The arginine salt form has been promoted as more stable by some vendors. Both contain the same active peptide sequence — the difference is the counterion used during synthesis. There is no published evidence that one form is significantly more effective than the other.
Related Tools & Guides
- Reconstitution Calculator — Calculate exact BPC-157 dosage and syringe units
- Protocol Builder — Build a complete BPC-157 protocol with timing
- Comparison Tool — Compare BPC-157 head-to-head with any peptide
- Interaction Checker — Verify BPC-157 stacking safety
- Peptide Glossary — Look up VEGF, angiogenesis, and other key terms
- Mixing & Administration Guide — Step-by-step injection technique
Related Articles
- BPC-157 vs TB-500: Which Repair Peptide Is Better?
- BPC-157 + TB-500 Stack: The Complete Repair Protocol
- How to Reconstitute Peptides: Step-by-Step Guide
- Best Peptides for Healing Injuries
- Are Peptides Legal? 2026 Country-by-Country Guide
Sources
- Seiwerth, S. et al. (2018). BPC 157's effect on healing. Journal of Physiology and Pharmacology, 69(6). PMID: 30898980
- Sikiric, P. et al. (2014). Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology, 14(8), 857–865. PMID: 27306034
- Chang, C. H. et al. (2014). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774–780. PMID: 21030672
- Huang, T. et al. (2015). BPC157 accelerates wound healing via FAK-paxillin pathway activation. Life Sciences, 128, 62–67. PMID: 25744395
- Sikiric, P. et al. (2016). Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions. Life Sciences, 35, 112–127. PMID: 27593383
- Staresinic, M. et al. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research, 21(6), 976–983. PMID: 14554207
- Cerovecki, T. et al. (2010). Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research, 28(9), 1155–1161. PMID: 20225319
- Novinscak, T. et al. (2008). Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surgery Today, 38(8), 716–725. PMID: 18668316
- Sebecic, B. et al. (1999). Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits. Journal of Orthopaedic Research, 17(4), 505–509. PMID: 10459755
- Sikiric, P. et al. (2020). Stable gastric pentadecapeptide BPC 157 — Robert's cytoprotection/adaptive cytoprotection/organoprotection and Selye's stress coping response. Progress in Brain Research, 261, 45–90. PMID: 33419512
- Gjurasin, M. et al. (2010). Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regulatory Peptides, 160(1–3), 33–41. PMID: 19903499
- Tudor, M. et al. (2010). BPC 157 and the NO system in traumatic brain injury. European Journal of Pharmacology, 627(1–3), 194–199. PMID: 19853596
- Sikiric, P. et al. (2018). Cardioprotective effects of pentadecapeptide BPC 157. Curr Pharm Des, 24(30), 3540–3548. PMID: 30370846
- Ruenzi, M. et al. (2019). Pentadecapeptide BPC 157 in inflammatory bowel disease — a pilot study. Meeting abstract, UEGW 2019.
- Sikiric, P. et al. (2013). Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design, 19(1), 76–83. PMID: 22950502
Medical Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. BPC-157 is not FDA-approved for any indication. Peptide therapy should be pursued under the supervision of a licensed healthcare professional. Always consult with a qualified medical provider before beginning any peptide protocol.
© 2026 GreyPeptides.com — All rights reserved.
This article is for educational purposes only and does not constitute medical advice. Consult a licensed medical professional before considering any peptide therapy.